These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 15731064)
1. Interactions of OspA monoclonal antibody C3.78 with Borrelia burgdorferi within ticks. Gipson CL; de Silva AM Infect Immun; 2005 Mar; 73(3):1644-7. PubMed ID: 15731064 [TBL] [Abstract][Full Text] [Related]
2. OspA immunization decreases transmission of Borrelia burgdorferi spirochetes from infected Peromyscus leucopus mice to larval Ixodes scapularis ticks. Tsao J; Barbour AG; Luke CJ; Fikrig E; Fish D Vector Borne Zoonotic Dis; 2001; 1(1):65-74. PubMed ID: 12653137 [TBL] [Abstract][Full Text] [Related]
3. Influence of outer surface protein A antibody on Borrelia burgdorferi within feeding ticks. de Silva AM; Zeidner NS; Zhang Y; Dolan MC; Piesman J; Fikrig E Infect Immun; 1999 Jan; 67(1):30-5. PubMed ID: 9864192 [TBL] [Abstract][Full Text] [Related]
4. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. de Silva AM; Telford SR; Brunet LR; Barthold SW; Fikrig E J Exp Med; 1996 Jan; 183(1):271-5. PubMed ID: 8551231 [TBL] [Abstract][Full Text] [Related]
5. Does host complement kill Borrelia burgdorferi within ticks? Rathinavelu S; Broadwater A; de Silva AM Infect Immun; 2003 Feb; 71(2):822-9. PubMed ID: 12540562 [TBL] [Abstract][Full Text] [Related]
6. Production of outer surface protein A by Borrelia burgdorferi during transmission from infected mammals to feeding ticks is insufficient to trigger OspA seroconversion. Woodman ME; Cooley AE; Stevenson B FEMS Immunol Med Microbiol; 2008 Nov; 54(2):277-82. PubMed ID: 18793197 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody. Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491 [TBL] [Abstract][Full Text] [Related]
8. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Scheckelhoff MR; Telford SR; Hu LT Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863 [TBL] [Abstract][Full Text] [Related]
9. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA. Eschner AK; Mugnai K Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386 [TBL] [Abstract][Full Text] [Related]
10. T helper cell priming of mice to Borrelia burgdorferi OspA leads to induction of protective antibodies following experimental but not tick-borne infection. Zhong W; Gern L; Kramer M; Wallich R; Simon MM Eur J Immunol; 1997 Nov; 27(11):2942-7. PubMed ID: 9394822 [TBL] [Abstract][Full Text] [Related]
11. Differential efficacy of passive immunisation against infection by Lyme disease spirochaetes transmitted by partially fed vector ticks. Shih CM; Liu LP J Med Microbiol; 1998 Sep; 47(9):773-9. PubMed ID: 9736159 [TBL] [Abstract][Full Text] [Related]
12. Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: Implications for vaccine development. Izac JR; Oliver LD; Earnhart CG; Marconi RT Vaccine; 2017 May; 35(24):3178-3185. PubMed ID: 28479174 [TBL] [Abstract][Full Text] [Related]
13. Attachment of Borrelia burgdorferi within Ixodes scapularis mediated by outer surface protein A. Pal U; de Silva AM; Montgomery RR; Fish D; Anguita J; Anderson JF; Lobet Y; Fikrig E J Clin Invest; 2000 Aug; 106(4):561-9. PubMed ID: 10953031 [TBL] [Abstract][Full Text] [Related]
14. Outer surface protein A protects Lyme disease spirochetes from acquired host immunity in the tick vector. Battisti JM; Bono JL; Rosa PA; Schrumpf ME; Schwan TG; Policastro PF Infect Immun; 2008 Nov; 76(11):5228-37. PubMed ID: 18779341 [TBL] [Abstract][Full Text] [Related]
15. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA. Koide S; Yang X; Huang X; Dunn JJ; Luft BJ J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380 [TBL] [Abstract][Full Text] [Related]
16. A reverse transcriptase-polymerase chain reaction assay of Borrelia burgdorferi 16S rRNA for highly sensitive quantification of pathogen load in a vector. Ornstein K; Barbour AG Vector Borne Zoonotic Dis; 2006; 6(1):103-12. PubMed ID: 16584333 [TBL] [Abstract][Full Text] [Related]
17. A new approach to a Lyme disease vaccine. Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174 [TBL] [Abstract][Full Text] [Related]
18. Vaccination against Lyme disease: past, present, and future. Embers ME; Narasimhan S Front Cell Infect Microbiol; 2013; 3():6. PubMed ID: 23407755 [TBL] [Abstract][Full Text] [Related]
19. Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies. Kurtenbach K; Dizij A; Voet P; Hauser P; Simon MM Vaccine; 1997 Oct; 15(15):1670-4. PubMed ID: 9364698 [TBL] [Abstract][Full Text] [Related]
20. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters. Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]